1Cheng J W. Bosentan. Heart Dis, 2003, 5: 161-169.
2Muller D N, Mervaala E M, Schmidt F, et al. Effect of bosentan on NF-Kb, inflammation, and tissue factor in angiotensin Ⅱ-induced and organ damage. Hypertension, 2000, 36: 282-290.
3Piacentini L, Honda M, Saida K, et al. Endotholin-1 Stimulates Cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol, 2000, 32:565-576.
4Berigm A, Remuzzi G. Endothlin antagonists. Lancet, 1999, 353: 133-138.
5Weber C, Schmitt R, Birmboeck H, et al. Multiple-dose pharmacokinetics safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol, 1999, 39: 703-714.
6Fattinger K ,Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the Canalicular bile salt export pump: a potential mechanism for hepatic adverse reaction. Clin Pharmacol Ther, 2001, 69: 223-231.
7Rashid A,Lehman S, Romano P, et al. Primary pulmonary hypertension. Heart Dis, 2000, 2: 422-430.
8Bauer M, Wilkens H, Langer C F, et al. elective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation, 2002, 105: 1034-1036.
9Chennick R N, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension. a randomized placebo controlled study. Lancet, 2001, 38: 1119-1123.
10Rubin L J, Badesch D B, Barst R J, et al. Bosentan patients therapy for pulmonary arterial hypertension. N Engl J Med, 2002, 346: 896-903.
